File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oleanolic acid loaded PEGylated PLA and PLGA nanoparticles with enhanced cytotoxic activity against cancer cells

TitleOleanolic acid loaded PEGylated PLA and PLGA nanoparticles with enhanced cytotoxic activity against cancer cells
Authors
Keywordscytotoxicity
nanoparticles
oleanolic acid
PEGylation
PLA
PLGA
Issue Date2015
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html
Citation
Molecular Pharmaceutics, 2015, v. 12 n. 6, p. 2112-2125 How to Cite?
AbstractOleanolic acid (OA) is a natural triterpenoid with anticancer properties, but its hydrophobic nature and poor aqueous solubility pose challenges in pharmaceutical formulation development. The present study aimed at developing OA-loaded mPEG-PLGA or mPEG-PLA nanoparticles (NPs) to improve the delivery of OA. The NPs were prepared by nanoprecipitation, and their physicochemical properties were characterized. The OA encapsulation efficiency of the NPs was between 40 and 75%. The size of the OA-loaded NPs was around 200-250 nm, which fell within the range required for tumor targeting by means of the enhanced permeability and retention (EPR) effect, and the negatively charged NPs remained physically stable for over 20 weeks with no aggregation observed. The OA-loaded NPs produced significant cytotoxic effects through apoptosis in cancer cell lines. Overall, the OA-loaded mPEG-PLGA NPs and mPEG-PLA NPs shared similar physicochemical properties. The former, especially the OA-loaded mPEG-P(D,L)LGA NPs, were more cytotoxic to cancer cells and therefore were more efficient for OA delivery. © 2015 American Chemical Society.
Persistent Identifierhttp://hdl.handle.net/10722/211890
ISSN
2021 Impact Factor: 5.364
2020 SCImago Journal Rankings: 1.130
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMan, DKW-
dc.contributor.authorCasettari, L-
dc.contributor.authorCepsi, C-
dc.contributor.authorBonacucina, G-
dc.contributor.authorPalmieri, GF-
dc.contributor.authorSze, SCW-
dc.contributor.authorLeung, GPH-
dc.contributor.authorLam, JKW-
dc.contributor.authorKwok, PCL-
dc.date.accessioned2015-07-21T02:15:03Z-
dc.date.available2015-07-21T02:15:03Z-
dc.date.issued2015-
dc.identifier.citationMolecular Pharmaceutics, 2015, v. 12 n. 6, p. 2112-2125-
dc.identifier.issn1543-8384-
dc.identifier.urihttp://hdl.handle.net/10722/211890-
dc.description.abstractOleanolic acid (OA) is a natural triterpenoid with anticancer properties, but its hydrophobic nature and poor aqueous solubility pose challenges in pharmaceutical formulation development. The present study aimed at developing OA-loaded mPEG-PLGA or mPEG-PLA nanoparticles (NPs) to improve the delivery of OA. The NPs were prepared by nanoprecipitation, and their physicochemical properties were characterized. The OA encapsulation efficiency of the NPs was between 40 and 75%. The size of the OA-loaded NPs was around 200-250 nm, which fell within the range required for tumor targeting by means of the enhanced permeability and retention (EPR) effect, and the negatively charged NPs remained physically stable for over 20 weeks with no aggregation observed. The OA-loaded NPs produced significant cytotoxic effects through apoptosis in cancer cell lines. Overall, the OA-loaded mPEG-PLGA NPs and mPEG-PLA NPs shared similar physicochemical properties. The former, especially the OA-loaded mPEG-P(D,L)LGA NPs, were more cytotoxic to cancer cells and therefore were more efficient for OA delivery. © 2015 American Chemical Society.-
dc.languageeng-
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html-
dc.relation.ispartofMolecular Pharmaceutics-
dc.subjectcytotoxicity-
dc.subjectnanoparticles-
dc.subjectoleanolic acid-
dc.subjectPEGylation-
dc.subjectPLA-
dc.subjectPLGA-
dc.titleOleanolic acid loaded PEGylated PLA and PLGA nanoparticles with enhanced cytotoxic activity against cancer cells-
dc.typeArticle-
dc.identifier.emailMan, DKW: u3001488@connect.hku.hk-
dc.identifier.emailSze, SCW: stephens@hku.hk-
dc.identifier.emailLeung, GPH: gphleung@hkucc.hku.hk-
dc.identifier.emailLam, JKW: jkwlam@hku.hk-
dc.identifier.emailKwok, PCL: pclkwok@hku.hk-
dc.identifier.authoritySze, SCW=rp00514-
dc.identifier.authorityLeung, GPH=rp00234-
dc.identifier.authorityLam, JKW=rp01346-
dc.identifier.authorityKwok, PCL=rp01540-
dc.identifier.doi10.1021/acs.molpharmaceut.5b00085-
dc.identifier.pmid25881668-
dc.identifier.scopuseid_2-s2.0-84930625166-
dc.identifier.hkuros244397-
dc.identifier.volume12-
dc.identifier.issue6-
dc.identifier.spage2112-
dc.identifier.epage2125-
dc.identifier.isiWOS:000355637900041-
dc.publisher.placeUnited States-
dc.identifier.issnl1543-8384-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats